InvestorsHub Logo
Followers 1113
Posts 117788
Boards Moderated 3
Alias Born 03/27/2007

Re: uranium-pinto-beans post# 355838

Friday, 12/09/2022 8:29:18 AM

Friday, December 09, 2022 8:29:18 AM

Post# of 363128
Arcellx announces continued robust long-term responses from its CART-ddBCMA Phase 1 expansion trial in patients with relapsed or refractory multiple myeloma and additional pipeline progress (halted) (21.68)
100% ORR at both CART-ddBCMA dose levels; deep and durable responses observed in patients with poor prognostic factors.
27 of 38 (71%) evaluable patients reached CR/sCR; 20 of 25 patients (80%) dosed > 12 months ago or had their 12-month follow-up visit by November 22, 2022 have reached CR/sCR.
No cases of Grade >3 CRS at RP2D and no delayed neurotoxicity or parkinsonian-like events.
First patients dosed in iMMagine-1 Phase 2 clinical trial with pivotal drug product.
Initiated the Phase 1 clinical trial of ACLX-002 for the treatment of patients with AML/MDS.
Management to host a live webcast event with an expert panel of clinicians to discuss the CART-ddBCMA clinical results on Sunday, December 11, 2022, at 11:00 AM CT.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.